शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
HIKALNSEHikal Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Wed, 11 Feb, 2026 · 16:45 IST

Hikal declares Rs 0.20 interim dividend; Q3 swings to net loss

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+10.8%Reaction day
₹190.00
prior close
₹197.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+11.3% vs market
Pharmaceuticals peers, median of 157sector-0.7%+11.4% vs sector

On the reaction day the stock moved 11.3 pts more than Nifty Microcap 250 and 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+5.4
10m
+7.0
15m
+7.2
30m
+8.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+10.8-0.5+11.3-0.7+11.4
Next day
+12.9-2.0+14.9-1.4+14.4
2d
+10.1-2.7+12.7-2.1+12.2
3d
+7.6-1.7+9.3-1.6+9.2
4d
+8.4-1.4+9.9-1.6+10.0
5d
+6.3-2.8+9.1-2.5+8.8
1w
+7.6-2.8+10.4-2.9+10.5
15d
-4.7-8.4+3.7-6.5+1.8
1m
-4.9-9.1+4.2-6.6+1.7
2m
-4.2-4.0-0.2-3.3-0.9
3m
+5.2+2.6+2.5+0.7+4.4
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hikal board declared an interim dividend of Rs 0.20 per share (10 percent) with record date February 17, 2026. Q3 FY26 swung to a net loss of Rs 59 million from a Rs 173 million profit a year ago, hit by a Rs 380 million exceptional charge from new Labour Codes. Revenue rose 10 percent to Rs 4,943 million. 9-month loss was Rs 633 million. Auditor issued a modified review on pending revenue recognition review and environmental case at the Supreme Court.

Likely market impact

Small interim dividend for shareholders, but Q3 net loss, modified audit, and USFDA warning letter raise near-term concerns.